DoD supports further development of plasma technology

10/6/2011 | American City Business Journals

The Defense Department has awarded Entegrion a $43.7 million contract to further develop the biotech company's Resusix plasma product. The technology, which the company says provides a better alternative to frozen blood plasma, would enable military staffers to dry and store plasma that they could use in combat situations.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI